patent ductus arteriosus
Conditions
Interventions
treatment group:Early targeted therapy with ibuprofen
contral group:5% glucose solution
Observation group:N/A
Sponsors
Chengdu Women‘s and Children’s Central Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ? Preterm infants with gestational age < 28 weeks and ultra-low birth weight infants with birth weight < 1000g; ? Informed consent of the legal guardian.
Exclusion criteria
Exclusion criteria: ? Those who died or gave up treatment within 1 day after birth; ? Patients with any of the following conditions: PDA right-to-left shunt time in the whole cardiac cycle ratio of =30% or severe pulmonary hypertension; Patients with severe gastrointestinal bleeding, confirmed or suspected NEC (Bell stage II or above), and hydrocortisone use within 12 hours before enrollment; Platelet count 120umol/L or urine volume < 0.5ml/Kg/h; Severe congenital heart malformations (excluding PDA and patent foramen ovale); Associated with other congenital diseases that may cause abnormal development of the nervous system (e.g., genetic chromosomal disorders, congenital brain abnormalities, etc.); The mother had a history of using ibuprofen in the last 6 months; Those who cannot start the trial within 72 hours for other reasons; Patients who did not use umbilical artery catheterization after birth; ? The legal guardian did not agree to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Closure of ductus arteriosus; | — |
Countries
China
Contacts
Public ContactLI Huaying
Chengdu Women‘s and Children’s Central Hospital
Outcome results
None listed